KalVista Pharma Q1 EPS $(0.74) Beats $(0.86) Estimate; Cash Position Of $123.3M
Portfolio Pulse from Benzinga Newsdesk
KalVista Pharma reported Q1 losses of $(0.74) per share, beating the analyst consensus estimate of $(0.86) by 13.95 percent. This is a 21.28 percent increase over losses from the same period last year. The company's cash position stands at $123.3M.
September 07, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
KalVista Pharma's Q1 earnings beat estimates, with losses less than expected. This could be seen as a positive sign by investors, potentially leading to a short-term increase in stock price.
KalVista Pharma's Q1 earnings beat analyst estimates, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and a short-term increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100